This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (2)  • Contact me when this article is cited  Related Content  • Related letter  • Related article  • Similar articles in this journal  Topic Collections  • Evidence-Based Medicine  • Randomized Controlled Trial  • Psychopharmacology  • Schizophrenia  • Alert me on articles by topic

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

We read with interest the impressive meta-analysis by Davis et al¹ of the efficacy of second-generation antipsychotics (SGAs) published in the ARCHIVES but were concerned about its inadequate consideration of some important methodologic limitations that may have significantly detracted from the veracity of their conclusions. There are approximately 50 different antipsychotic medications available in the world; of the 20 currently available in the United States, 6 (clozapine, risperidone, olanzapine, quetiapine fumarate, ziprasidone hydrochloride, and aripiprazole) are labeled SGAs. Perhaps because of their presumed broader spectrum of efficacy and better motor adverse-effect profile, SGAs collectively constitute more than 90% of all antipsychotic prescriptions in the United States at this time. Despite the wide popularity of these medications and their rapid adoption in general clinical practice, there are limited data on how they compare with each other with regard to their overall efficacy. In an effort to address this issue, Davis . . . [Full Text of this Article]

AUTHOR INFORMATION
Rajiv Tandon, MD; Henry A. Nasrallah, MD

RELATED LETTER

Subjecting Meta-analyses to Closer Scrutiny: Little Support for Differential Efficacy Among Second-Generation Antipsychotics at Equivalent Doses—Reply
John M. Davis, Nancy Chen, and Ira D. Glick
Arch Gen Psychiatry. 2006;63(8):937-939.
EXTRACT | FULL TEXT  

RELATED ARTICLE

A Meta-analysis of the Efficacy of Second-Generation Antipsychotics
John M. Davis, Nancy Chen, and Ira D. Glick
Arch Gen Psychiatry. 2003;60(6):553-564.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Efficacy and Tolerability of Second-Generation Antipsychotics in Children and Adolescents With Schizophrenia
Kumra et al.
Schizophr Bull 2008;34:60-71.
ABSTRACT | FULL TEXT